

Hybrigenics updates its web communication

Hybrigenics launches a new website dedicated to its Services subsidiary and a new version of its corporate website

Paris, 05 September 2012 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases, today announces the launch of a new website dedicated to Hybrigenics Services, its subsidiary specialised in protein interaction research, and of a new version of its corporate website.

Hybrigenics Services' website (www.hybrigenics-services.com) has been specifically designed to get optimal scientific and commercial impact on its main customer base: researchers in life sciences from all around the world. The new version of Hybrigenics' corporate website (www.hybrigenics.com) is targeting its investor base and potential pharmaceutical partners. Both websites emphasize user-friendliness, clarity and proximity.

"We invite our shareholders and anyone with an interest in Hybrigenics to visit our web sites and let us know their feed-back through the contact page," said Remi Delansorne, Hybrigenics' CEO.

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere[®], which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol has recently been studied in a clinical trial for the treatment of moderate-to-severe psoriasis, and is about to be tested in chronic lymphocytic leukemia patients.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.

Hybrigenics Services (www.hybrigenics-services.com), a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics

Rémi Delansorne
CEO
Tel.: +33 (0)1 58 10 38 00
investors@hybrigenics.com

NewCap.

Financial communication
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
hybrigenics@newcap.fr